Immunochemotherapy in human lung cancer using the streptococcal agent OK-432
- 1 May 1976
- Vol. 37 (5) , 2201-2203
- https://doi.org/10.1002/1097-0142(197605)37:5<2201::aid-cncr2820370507>3.0.co;2-q
Abstract
Streptococcal agent OK-432 was administered at maintenance levels with conventional inductive chemotherapeutic agents to stage III and IV lung cancer patients. Survival rates were longer in patients treated with OK-432 than in patients treated without OK-432. An enhancement of lymphocyte blastogenic activity and a delayed PPD skin reaction were found in patients treated by OK-432. A low grade fever was present as a side effect of this agent in some patients. The results suggest that OK-432 may be a useful immunotherapeutic agent in combination with induction chemotherapy in reducing host damage in advanced stages of lung cancer.This publication has 2 references indexed in Scilit:
- A rapid microtechnique for in vitro stimulation of human lymphocytes by phytohemagglutininClinical Immunology and Immunopathology, 1973
- Studies on the Anticancer and Streptolysin S‐Forming Abilities of Hemolytic StreptococciJapanese Journal of Microbiology, 1967